Private Wealth Management Group’s BioMarin Pharmaceuticals BMRN Stock Holding History

Private Wealth Management Group’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2K	Buy	35 +22	+169%	+$1.21K	﹤0.01%	1167
2026 Q1	$735	Hold	13	–	–	﹤0.01%	1301
2025 Q4	$773	Hold	13	–	–	﹤0.01%	1316
2025 Q3	$705	Buy	13 +12	+1,200%	+$686	﹤0.01%	1364
2025 Q2	$55	Sell	1 -140	-99%	-$8.24K	﹤0.01%	1485
2025 Q1	$9.97K	Buy	141 +26	+23%	+$1.75K	﹤0.01%	474
2024 Q4	$7.56K	Buy	115 +10	+10%	+$670	﹤0.01%	583
2024 Q3	$7.38K	Sell	105 -26	-20%	-$2.17K	﹤0.01%	573
2024 Q2	$10.8K	Buy	131 +33	+34%	+$2.75K	﹤0.01%	426
2024 Q1	$8.56K	Sell	98 -28	-22%	-$2.51K	﹤0.01%	457
2023 Q4	$12.1K	Buy	+126	New	+$11.1K	0.01%	367

Other funds holding BMRN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Norges Bank Oslo, Norway $1T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

VPC

Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Private Wealth Management Group's BMRN Position: Q2 2026 in Review

Private Wealth Management Group increased its BioMarin Pharmaceuticals (BMRN) stake by 169% in Q2 2026, buying an estimated $1.21K and bringing the position to 35 shares worth $2K. The position accounts for ﹤0.01% of the portfolio, ranked #1167.

Private Wealth Management Group first reported a position in BMRN in Q4 2023 and has held it in 11 quarters since. The position peaked at $12.1K in Q4 2023. 565 funds tracked by Wall St. Rank hold BMRN as of Q2 2026.

Private Wealth Management Group held 35 shares of BioMarin Pharmaceuticals worth $2K as of Q2 2026.
Private Wealth Management Group bought 22 BioMarin Pharmaceuticals shares in Q2 2026, an estimated $1.21K.
BioMarin Pharmaceuticals made up ﹤0.01% of Private Wealth Management Group's portfolio in Q2 2026, its #1167 holding.
Private Wealth Management Group first reported a position in BioMarin Pharmaceuticals in Q4 2023 and has held it in 11 quarters since.
Private Wealth Management Group's BioMarin Pharmaceuticals position peaked at $12.1K in Q4 2023.
565 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2026.

Based on Private Wealth Management Group's 13F filing for Q2 2026, filed 27 Jul 2026.